TetraLogic Pharmaceuticals Corporation
TLOG
TLOG was delisted on the 3rd of November, 2016.
19 hedge funds and large institutions have $205K invested in TetraLogic Pharmaceuticals Corporation in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 7 closing their positions.
34% more capital invested
Capital invested by funds: $153K → $205K (+$52K)
0.86% less ownership
Funds ownership: 3.54% → 2.68% (-0.86%)
24% less funds holding
Funds holding: 25 → 19 (-6)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.22K |
| 2 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$56 |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$36 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lazard Asset Management
New York
|
-$13K |
| 2 |
GA
Geneva Advisors
Chicago,
Illinois
|
-$9K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$9K |
| 4 |
Bank of New York Mellon
New York
|
-$5.07K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.78K |
TLOG Hedge Fund Activity: Q2 2016 in Review
19 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in TetraLogic Pharmaceuticals Corporation (TLOG) for Q2 2016, worth a combined $205K — up 34% from $153K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TLOG and 1 opened new positions — a net loss of 6 holders — while 5 trimmed existing stakes and 2 added.
The largest buyer was Vanguard Group, adding an estimated $7.22K. The largest seller was Lazard Asset Management, exiting entirely with an estimated $13K sold.
- 19 institutional investors held TetraLogic Pharmaceuticals Corporation (TLOG) as of Q2 2016, down from 25 in Q1 2016.
- Funds reported $205K of TetraLogic Pharmaceuticals Corporation stock for Q2 2016, up 34% quarter-over-quarter.
- 1 fund opened new TetraLogic Pharmaceuticals Corporation positions in Q2 2016 and 7 closed out, a net change of -6 holders.
- The largest TetraLogic Pharmaceuticals Corporation buyer in Q2 2016 was Vanguard Group, an estimated $7.22K added.
- The largest TetraLogic Pharmaceuticals Corporation seller in Q2 2016 was Lazard Asset Management, an estimated $13K sold.
Based on aggregated 13F filings for Q2 2016.